Skip to main content

Advertisement

Table 1 Summary characteristics of CQ-treated patients

From: Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy)

  Cases* Controls p-value (two-sided t-test)
Number of Individuals 24 13 -
Mean Age (S.D.) [years] 61.18 (10.45) 49.11 (9.74) 0.0016
Treatment Duration (S.D.) [months] 153.1 (97.77) 121.8 (58.74) 0.2327
Daily dose per body weight (S.D.) [mg/kg] 4.00 (1.26) 3.90 (0.84) 0.7966
Daily dose per ideal weight (S.D.) [mg/kg] 4.90 (1.25) 4.07 (0.31) 0.0078
Fraction of Individuals > 60 years 0.71 0.15 -
Male [%] 0.04 0.23 0.1622
  1. *Patients treated with CQ and affected with toxic maculopathy.
  2. Patients treated with CQ and no signs of toxic maculopathy.